Skip to main content
ISOP ACoP 2025 Annual Conference Main banner

Hongtao Yu, PhD (he/him/his)

Associate Director, Clinical Pharmacology and Quantitative Pharmacology
AstraZeneca, United States

Hongtao Yu, PhD, is an Associate Director and Clinical Pharmacometrician at AstraZeneca. He completed his postdoctoral training at the University of Georgia, where he worked on quantitative pharmacology and systems modeling in cardiorenal disease. Since joining AstraZeneca, Dr. Yu has focused on applying clinical pharmacology and pharmacometrics to inform drug development across metabolic, cardiovascular, and renal indications. His work integrates population PK, PK/PD, exposure–response, quantitative systems pharmacology, and model-based meta-analysis (MBMA) approaches to support decision-making from first-in-human studies to late-phase development. Therapeutic area experience spans obesity, diabetes, dyslipidemia, chronic kidney disease, and inflammatory and respiratory conditions. Contributions include model-based analyses of GLP-1 receptor agonists, dual incretin agonists, oral PCSK9 inhibitors, and novel biologics. He has emphasized the role of model-informed drug development (MIDD) in dose selection, trial design, and regulatory interactions, with publications demonstrating how quantitative approaches can guide development strategies and clarify complex exposure–response relationships. Dr. Yu’s work bridges mechanistic insight with applied clinical pharmacology, contributing to the advancement of innovative therapies and highlighting the impact of pharmacometrics in accelerating decision-making and improving the probability of success in clinical development.

Disclosure information not submitted.

Presentation(s):

Email Hongtao